资讯

Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment
Q1 2025 Management View CEO David Meeker highlighted progress in the Phase 3 trial for acquired hypothalamic obesity (HO) and ...